Trial Profile
Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- 28 Oct 2019 Status changed from recruiting to completed.
- 18 Apr 2019 Planned End Date changed from 1 Feb 2019 to 1 Aug 2019.
- 18 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Aug 2019.